Moreover, in both naturally aged mice and progeria models (Ercc1 Δ/−), inhibition of activin A, through either antibodies against its receptors (ActRII) or soluble ActRII ligand traps, improves age-associated cardiac dysfunction and remodeling[161,164]. The gene discussed is ACVR2A; the disease is progeroid syndrome.